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Abstract
Diabetic foot syndrome demonstrates wound chronicity due to impaired tissue perfusion in lower limbs. Previous studies showed interferon-gamma (IFN-γ), a 
central inflammatory mediator in diabetic foot syndrome, to induce the truncated form of tryptophanyl-tRNA synthetase (mini-TrpRS) that has strong angiostatic 
properties. Recently we reported that mini-TrpRS signalling could be blocked in the presence of IFN-γ with D-tryptophan in vitro. Here we discuss the IFN-γ/
mini-TrpRS axis in the pathology of diabetic foot syndrome and emerging therapeutic options.
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Background
Approximately 25% of patients with diabetes will develop diabetic 
foot syndrome [1]. This severe complication of progressing diabetes is 
responsible for approximately 85% of lower limb amputations associated 
with a dramatic decrease in quality of life and increased mortality [2]. 
The aetiology of diabetes can be traced to well-recognized risk factors 
such as genetic predisposition, ageing, male sex, and lifestyle factors, 
including unhealthy diet and low physical activity. Most of these 
traditional risk factors are either non-modifiable (genetics, ageing, sex) 
or hard to modify in diabetic foot syndrome patients such as exercise or 
even diet. The substantial evidence, however, suggests that inflammatory 
pathways are the principal and common pathogenic mediators in the 
course of diabetes and its complications under stimuli of traditional 
risk factors [3,4]. Among them, interferon-gamma (IFN-γ), an 
important pro-inflammatory cytokine primarily involved in the host 
defence against acute infections, is also chronically elevated in patients 
with diabetes and considered as a crucial risk factor for diabetic foot 
syndrome [5,6]. In particular, IFN-γ is a critical cytokine in angiostatic 
responses that impairs normal tissue perfusion and microvascular 
reaction to injury [7]. Despite the importance of the anti-angiogenic 
properties of IFN-γ, the molecular mechanisms by which IFN‐γ elicits 
its actions on vasculature remained poorly understood. Our recent 
findings support novel thinking to how IFN-γ may only indirectly 
contribute to the pathology of diabetic foot syndrome by up-regulating 
angiostatic pathways and hold promising treatment implications for 
patients with this debilitating complication of diabetes.
The problem
Impaired tissue perfusion in lower limbs is a leading cause of 
wound chronicity in patients with progressing diabetes. Innovations 
in enhancing wound revascularization would lead to a significant 
improvement in patient care and their quality of life.
The rationale and solution
The WARS1 gene-encoded human tryptophanyl-tRNA synthetase 
(TrpRS) exists as two forms; a full-length protein and a truncated 
variant known as ‘mini-TrpRS’ in which most of the N-terminal 
domain is deleted during alternative splicing of the WARS1 precursor 
mRNA [8]. IFN-γ strongly stimulates the production of mini-TrpRS, 
and it is the only human tRNA-ligase whose expression is induced 
by IFN-γ [9]. The significance of this phenomenon was recognized 
following the discovery that mini-TrpRS, unlike its full-length variant, 
is also a potent negative regulator of angiogenesis outside its primary 
role in aminoacylation [10-12]. Angiostatic activities of human mini-
TrpRS were extensively studied using several human and animal 
models, including human umbilical vein endothelial cells (HUVEC) 
migration and proliferation, chick chorioallantoic membrane, mouse 
matrigel, and mouse retinal angiogenesis assays [10]. Importantly, our 
recent discovery shows that mini-TrpRS signalling in the presence of 
IFN-γ in vitro can be effectively blocked with D-tryptophan, a cognate 
amino acid acting as a decoy substrate for mini-TrpRS [13]. It has 
become evident that mini-TrpRS signalling inevitably occurs in the 
context of more complex regulation mediated by IFN-γ to execute 
specific outcomes depending on the pathological environment and 
the cell type involved [13,14]. An important question, whether a direct 
neutralization of mini-TrpRS would limit the progression of diabetic 
foot syndrome, is posed. In this regard, D-tryptophan would appear 
an ideal intervention to be investigated in patients with diabetic foot 
syndrome. Chemically, D-tryptophan is an enantiomer of L-tryptophan, 
an essential amino acid found in most human proteins, and a precursor 
to the neurotransmitter serotonin, the hormone melatonin, and vitamin 
B3 [15]. In experimental models, D-tryptophan is readily cleared from 
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plasma, and there is no appreciable conversion of D-tryptophan to 
metabolically active L-tryptophan [16,17]. As such, side effects such as 
unintended stimulation of serotonin production in the brain [16] or 
other metabolic functions of the L-tryptophan [17] would be expected 
to be negligible in treated patients with a diabetic foot ulcer. Indeed, 
D-tryptophan, also known as NLG8189 and Indoximod (methylated 
D-tryptophan), has not been trialled exactly in patients with diabetic 
foot syndrome but oncological patients; the drug was investigated at 
a dose up to 2,000 mg twice daily, was well tolerated, and no patients 
discontinued treatment due to toxicity [18]. A dose up to 800 mg 
showed good oral bioavailability with a linear dose-response of the area 
under the curve (AUC) and the maximum serum concentration (Cmax) 
[18]. Within this frame of reference, studies investigating diabetic foot 
syndrome therapy based on D-tryptophan are planned for future work.
The therapy
We plan a double-blind, placebo-controlled clinical trial to evaluate 
the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamics 
(PD), and explore the effect of D-tryptophan combined with standard 
wound care compared to placebo in patients with diabetic foot 
syndrome. In phase 1a, we will assess a single ascending dose (SAD) 
followed by a multiple ascending dose (MAD) study over 12 weeks 
in phase 1b (Figure 1). The development of a novel pharmacological 
treatment based on D-tryptophan is directed at combining with the 
current standard of wound care to aid with the clinical management of 
this debilitating complication of diabetes. 
The primary objective is to assess the safety and pharmacokinetic 
tolerability of D-tryptophan in treated individuals (Phase 1a), with the 
secondary objective to assess the effect of D-tryptophan on biological 
markers of wound healing.
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Figure 1. Schematic of Phase 1a/b clinical trial of D-tryptophan for treating patients with 
diabetic foot syndrome
